Halozyme Therapeutics, Inc. $HALO Shares Acquired by Epoch Investment Partners Inc.

Key Points

• Epoch Investment Partners Inc. increased its holdings in Halozyme Therapeutics by 6.3%, acquiring an additional 48,936 shares, bringing its total ownership to 827,247 shares valued at approximately $52.79 million.
• Several hedge funds have significantly boosted their positions in Halozyme, with Caisse DE Depot ET Placement DU Quebec increasing its stake by 154.5%, now holding 910,169 shares valued at $58.08 million.
• Analysts have set varied price targets for Halozyme Therapeutics, with Wells Fargo & Company raising their target to $65.00, while Leerink Partners cut their rating and set a target of $47.00.

Epoch Investment Partners Inc. boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 827,247 shares of the biopharmaceutical company's stock after acquiring an additional 48,936 shares during the quarter. Epoch Investment Partners Inc. owned about 0.67% of Halozyme Therapeutics worth $52,787,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. SVB Wealth LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter worth about $33,000. Bessemer Group Inc. boosted its position in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Brooklyn Investment Group raised its position in Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 670 shares during the last quarter. Finally, Park Place Capital Corp lifted its stake in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 182 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $46,598,493.69. This represents a 2.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 80,000 shares of company stock valued at $4,532,600 in the last three months. 2.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on HALO. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research note on Tuesday, May 13th. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. The Goldman Sachs Group initiated coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Finally, Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $67.11.

Halozyme Therapeutics Stock Performance

HALO traded up $0.34 on Monday, reaching $73.15. The stock had a trading volume of 1,163,957 shares, compared to its average volume of 2,229,040. The business's 50-day moving average price is $60.68 and its two-hundred day moving average price is $59.28. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $74.07. The company has a market cap of $8.56 billion, a P/E ratio of 16.74, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company's quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.